Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each level. vvDD-hIL2 is a genetically modified vaccinia virus, derived from the virus previously used for smallpox vaccination. The modification is intended to target and destroy tumors while minimizing harm to healthy tissues by stimulating the body's immune response. Participants will receive an inj

Trial Details

NCT ID
NCT07001592
Phase
PHASE1
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • vvDD-hIL-2-RG-1
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Males or females age, 18 to \< 70 years at the time of consent
  • Histologically confirmed metastases from gastrointestinal tumors with molecular determinants for MSI and KRAS.
  • For microsatellite stable (MSS) tumors, subjects must have failed (or be ineligible for) standard 1st and 2nd line chemotherapy. For microsatellite…
  • Karnofsky Performance Status (KPS) of \> 70

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →